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Introduction: Cardiovascular diseases (CVD) are the
leading cause of mortality worldwide and diet is an
important contributor to CVD risk. Thus, several food
derivatives are being investigated for their beneficial
impact on reducing cardiometabolic risk factors, either
in risk groups or in healthy population as a preventive
measure. Wheat germ is a food by-product with high
nutritional value, especially as a concentrated source of
dietary fibre and essential fatty acids, but its
incorporation into the diet has been rare up to now.
Previous studies do not clarify the hypothesised
potential causal relationship between the consumption
of wheat germ and benefits for human health.
Methods and analysis: We are conducting a
randomised, double-blinded, crossover, placebo-
controlled clinical trial designed to assess the
physiological effects of daily consumption of wheat
germ-enriched bread (containing 6 g of wheat germ)
compared with non-enriched bread, over a 4-week
period with a 15-week follow-up, in a healthy human
population. A total of 55 participants (healthy
volunteers, aged 18–60) have been recruited from the
Porto metropolitan area in northern Portugal. Our aim
is to evaluate the health effects of wheat germ on
blood cholesterol and triglycerides, postprandial
glycaemic response, gastrointestinal function and
discomfort, and changes in intestinal microbiota and
insulin resistance as secondary outcomes. The study
follows the best practices for evaluating health claims
in food according to the European Food Safety
Authority (EFSA) scientific opinion, namely random
allocation, double blinding, reporting methods to
measure and maximise compliance, and validated
outcomes with beneficial physiological effects as
recommended by EFSA.
Ethics and dissemination: The study has been
approved by the Health Ethics Committee of São João
Hospital Centre (156-15) and the Ethics Committee of
Faculty of Medicine of the University of Porto
(PCEDCSS-FMUP07/2015). Results will be
disseminated through peer-reviewed publications and
presentations at international scientific meetings.
Trial registration number: NCT02405507;
pre-results.
INTRODUCTION
In recent decades, epidemiological studies
and clinical trials have established an associ-
ation between unhealthy dietary behaviours
and chronic diseases such as cardiovascular
diseases (CVD)1–3 and type 2 diabetes,4–6
which are leading causes of death in high-
income countries. In turn, some studies have
shown that populations can beneﬁt from the
incorporation of functional ingredients into
their diets, proposing that functional food
should be an integral part of public health
programmes.7 8 Accordingly, two recent sys-
tematic reviews conﬁrmed that whole grain
intake is associated with a reduced risk of
CVD.9 10
At the same time, governmental authorities
have limited health claims on food, allowing
only those based on solid scientiﬁc evidence.
Strengths and limitations of this study
▪ The outcomes measured in this clinical trial are
considered to be beneficial physiological effects,
according to the European Food Safety Authority
(EFSA) scientific opinion.
▪ The study follows the best practices for evaluat-
ing health claims in food, namely random alloca-
tion, double blinding, reporting methods to
measure and maximise compliance, and vali-
dated outcomes.
▪ The proposed trial will clarify the role of wheat
germ as a functional ingredient, namely whether
there is any benefit to including it in a normal
diet to reduce the symptoms associated with
gastrointestinal discomfort and the management
of hyperlipidaemia and glucose metabolism.
▪ Any statistically significant beneficial health could
contribute to providing the scientific evidence
needed for validation of health claims related to
wheat germ.
▪ Compliance with self-reported questionnaires
could decline over the 15-week follow-up.
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Examples of authorised health claims are the causal rela-
tionship between consumption of β-glucans from oats
and blood cholesterol levels,11 12 and a cause–effect rela-
tionship between walnut ingestion and improvement of
endothelium-dependent vasodilation.13
Wheat germ is the main by-product of the ﬂour
milling industry, and although it is considered an excel-
lent source of minerals, vitamins, ﬁbre and essential fatty
acids, it has been underused. Incorporation of wheat
germ in the diet is almost exclusively restricted to
animal feeding.14–16 Even so, ingestion of raw wheat
germ seems to reduce cholesterol and triglycerides (TG)
in rats17 18 and in human subjects with hypercholesterol-
aemia.19 20 In turn, Matteuzzi et al21 showed that inges-
tion of commercial wheat germ modiﬁes the human
colon microﬂora by lowering Gram-negative bacteria
such as coliforms, while increasing potentially health-
promoting bacteria, such as biﬁdobacteria and lactoba-
cilli. However, existing studies reporting wheat germ are
not sufﬁcient to validate a causal relationship, especially
due to the limited number of participants included.
Study aims
Our aim is to evaluate the impact of bread supplemen-
ted with wheat germ on blood cholesterol and TG, post-
prandial glycaemic response and insulin resistance;
gastrointestinal discomfort will be evaluated in parallel.
These outcomes are considered beneﬁcial physiological
effects by the European Food Safety Authority (EFSA),
and therefore this randomised crossover controlled trial
has been designed to provide scientiﬁc substantiation
for health claims related to wheat germ. Bread was
selected as the vehicle for wheat germ since it is a widely
consumed food product and is therefore the ideal
product to deliver functionality. Moreover, bread itself is
the main contributor to the glycaemic index (GI) of the
human diet22 and since it is regularly consumed, a small
change in its GI has been shown to have beneﬁcial
effects on health.22–24 The percentage of wheat germ
present in the enriched bread is 6%, a ﬁgure chosen




This study is a consortium-initiated, randomised, double-
blinded, crossover, placebo-controlled clinical trial
designed to assess the physiological effects of daily con-
sumption of wheat germ-enriched bread in a healthy
human population. The trial has been implemented at
the Faculty of Medicine of the University of Porto
(Portugal)’s Centre for Health Technology and Services
Research (CINTESIS).
Partners
The study is funded by the National Strategic Reference
Framework (Portugal), and is part of the
VALORINTEGRADOR project, jointly promoted by the
Portuguese agro-food industry and three different
Portuguese Research and Development (R&D) institu-
tions (the Centre for Biological Engineering at the
University of Minho, the College of Biotechnology at
the Portuguese Catholic University and CINTESIS). The
wheat bread supplemented with wheat germ was formu-
lated by the two latter R&D institutions in partnership
with GERM, South Africa, an agro-food company within
the ambit of VALORINTEGRADOR.
Recruitment, randomisation and blinding
Volunteers were recruited through public advertisements
in the university and faculty websites, and in online
newspapers. After an initial phone contact, volunteers
were invited to visit CINTESIS for a physical examination
and a brief questionnaire about their medical history in
order to check their eligibility to participate in the study.
Study inclusion and exclusion criteria are described in
table 1.
The full study protocol has been explained in depth
to the participants, who were instructed not to change
their normal diet during the study. A diary pack contain-
ing self-reported questionnaires and stool sampling kits
is being delivered to each participant on enrolment.
Eligible volunteers have been randomised into two
intervention groups (ratio 1:1) using a computer-
generated allocation sequence, and concealed through
sequentially numbered, opaque, sealed envelopes. The
allocation sequence was generated by a statistician who
had no involvement in recruitment and intervention
delivery. Groups 1 and 2 will take, daily, wheat bread
(100 g) named as A and B, respectively. Half of them
will start with A and the other half with B. A and B are
the intervention and placebo breads but the matching
code will be blinded during the trial, in all stages until
data analysis can be done. The participants, the princi-
pal investigator and the entire research team are
blinded to the bread code; only the company contracted
to produce the bread for the trial is aware of this code.
In this regard, we performed several tests and trials to
deﬁne the ﬁnal bread formula. Accordingly, we tested
the best formula for white bread preparation that masks
wheat germ supplementation regarding texture and
colour. Subsequently, different bread preparations in
which the percentage of wheat germ varied were tested.
We found that the bread enriched with 6% of wheat
germ has the best ratio in terms of bread texture,
volume and ﬂavour, being indistinguishable from the
placebo. This ﬁnding was validated by a group of experts
belonging to the VALORINTEGRADOR project.
Moreover, the bread (A or B) has been delivered to
each participant in opaque bags.
Intervention
An overview of the proposed study protocol is shown in
ﬁgure 1. This is a 15-week parallel group randomised
crossover trial. In the ﬁrst stage, eligible participants will
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undergo a 2-week run-in period. During this period, all
participants will ﬁll out a daily questionnaire to evaluate
defaecation frequency and stool consistency (using the
Bristol stool scale), as well as any gastrointestinal discom-
fort. During the run-in phase, participants do not
consume any study product. The second stage corre-
sponds to the randomised crossover phase. In this
phase, participants are randomised to take daily wheat
bread (100 g) supplemented with wheat germ (6 g/day;
the intervention arm) or to consume daily wheat bread
(100 g) without any supplementation (placebo; the
control arm) for a 4-week period. This will be followed
by a 5-week washout phase after which the participants
will be crossed over for a second 4-week phase.
The participants will ﬁll out a daily questionnaire to
determine compliance to the study protocol (daily con-
sumption of bread) and any changes in defaecation fre-
quency and stool consistency. We will use diaries to
assess compliance because there is no biomarker for
wheat germ intake. Participants have been instructed to
register and divulge any medication prescribed (not
declared during recruitment) or adverse events during
the study.
Follow-up and data collection
The evaluation will be performed at four different time
points: initial visit (T1, at the end of the 2-week run-in
period), intervention visit (T2, 4 weeks after T1),
washout (T3, at the end of the 5-week washout phase),
and ﬁnal visit (T4; at the end of the intervention stage,
after crossover). At each follow-up visit, a venous blood
sample will be collected in fasting state from which capil-
lary glycaemia will be measured using a glucose metre at
0, 30, 60 and 120 min after wheat bread (supplemented
with wheat germ or placebo) intake. In addition, the
participant will provide one stool sample from up to
72 hours beforehand, using the stool sampling kit pro-
vided by the research team. The self-reported question-
naires to score gastrointestinal discomfort and
constipation-related quality of life, and to evaluate per-
ceived stress during the run-in and intervention stages
will be delivered on follow-up. Table 2 shows the sched-
ule of visits and the variables under investigation in the
present study.
In order to increase retention and complete follow-up,
participants will receive a phone call 1-week before each
visit, and a reminder text message on the day before.
Self-collected and nurse-collected biological samples are
labelled with the participant’s study code assigned at
enrolment. The samples will be used only for the pur-
poses of this study, as stated in the protocol, and will be
destroyed at the end. The diary packages containing self-
reported questionnaires are also anonymised. Indeed,
all collected data will be linked to the participant code
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Adult men or women 1. Participant under prescription for medication for digestive
symptoms such as antispasmodic, laxatives and antidiarrhoeic
drugs or other digestive auxiliaries
2. Age 18–60 years 2. Relevant history, presence of any medical disorder or intake
of medication/dietary supplements, potentially interfering with
this trial at screening
3. Healthy volunteers free of chronic diseases with relevant
effect on the gastrointestinal system or on visceral motility
3. Participants with stool frequency of ≤1 stool every 7 days
4. Without a diagnosis of any digestive disease including
functional bowel disorders such as IBS
4. Participants not willing to avoid prebiotics and probiotics for
the duration of the study
5. Non-diabetic, no gastric bypass surgery 5. Intake of antibiotics in the past 4 weeks and laxatives in the
past 2 weeks
6. Fasting plasma glucose (finger-stick) <100 mg/dL
(<5.5 mmol/L)
6. Current use of medication for lowering blood cholesterol or
glucose
7. Non-smoker 7. Change of dietary habits within the 4 weeks prior to
screening (for instance, start of a diet high in fibre)
8. Willing and able to provide written informed consent 8. Pregnant participant or participant planning to become
pregnant during the study; breastfeeding participant
9. Participants with a history of drug, alcohol or other substance
abuse, or other factors limiting their ability to cooperate during
the study
10. Participants anticipating a change in their lifestyle or
physical activity levels since this may also influence the results
11. Known food intolerance or allergy
12. Participant involved in any clinical or food study within the
preceding month
IBS, irritable bowel syndrome.
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and only one member of the research team has access
to participant information. Moreover, only the research
coordinators will have access to all trial data.
Outcomes
Rationale for outcome measured
This randomised crossover controlled trial has been
designed to provide scientiﬁc substantiation of health
claims related to wheat germ, and therefore the primary
outcomes measured can be considered beneﬁcial physio-
logical effects by the EFSA.
The outcomes measured are grouped into two cat-
egories: (1) risk factors for CVD and (2) gastrointestinal
function. For cardiovascular health, changes in the
blood lipid proﬁle will be investigated by measuring low-
density lipoprotein (LDL) cholesterol, high-density lipo-
protein (HDL) cholesterol and TG as primary outcomes.
LDL cholesterol is a biomarker for CVD risk25 and
modiﬁcation of one of these markers (LDL, HDL or
TG) is considered a beneﬁcial physiological effect by the
EFSA.26 Blood concentration of C reactive protein
(CRP) will be also evaluated as a primary outcome since
CRP could be related to long-term risk of CVD.27 The
EFSA considers that the maintenance of low plasma con-
centrations of CRP might be beneﬁcial to human
health.28
The hypoglycaemic effect of wheat germ will be also
investigated. This food by-product
has a high content of dietary ﬁbre (∼18%),29 which
has been demonstrated to reduce blood glucose
Figure 1 Trial flow chart. WG+
is wheat bread with wheat germ
supplementation. WG− is wheat
bread without wheat germ.
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response after carbohydrate intake (postprandial).30
The intake of cereal ﬁbre and whole grains as part of a
diet with a low GI is a valuable strategy in the prevention
of type 2 diabetes mellitus and CVD in the general
population.31 Besides the postprandial glucose response,
the concentration of fasting plasma glucose and insulin
will be measured as a secondary outcome to calculate
homeostasis model assessment of insulin resistance
(HOMA-IR). Several studies have demonstrated an asso-
ciation between insulin resistance, type 2 diabetes and
CVD,32 33 while wheat germ is rich in α-linolenic acid
(nearly 0.5%),29 a dietary precursor of omega-3, which
has been reported to have beneﬁcial effects on insulin
resistance.34
Gastrointestinal discomfort will be assessed in the
context of the maintenance or improvement of digestive
function. Wheat germ modiﬁes colonic microbiota21
and it has previously been documented that these micro-
biota affect gut health in healthy individuals.35 36
Gastrointestinal discomfort affects 16% of the healthy
population and a reduction in its symptoms is consid-
ered to be an indicator of improved gastrointestinal
function.37 38 Patient-reported outcomes by means of
self-reported validated questionnaires will be used for
evaluation of gastrointestinal discomfort in this study.
The use of these questionnaires as outcome variables for
the scientiﬁc substantiation of health claims is accepted
by the EFSA.39 At the same time, the composition of
colonic bacterial microbiota will be analysed as a second-
ary outcome. Decreasing potentially pathogenic gastro-
intestinal microorganisms might be a beneﬁcial
physiological effect, according to experts at the
EFSA.40 41
Primary outcomes
The primary outcomes in this trial will be to demon-
strate the difference (change) between wheat bread sup-
plemented with wheat germ (6 g) and placebo in (1)
serum TG and total cholesterol as well as LDL and
HDL, (2) CRP, (3) postprandial blood glucose and (4)
gastrointestinal discomfort associated with constipation.
Analysis of TG; total, LDL and HDL cholesterol; and
CRP will be performed by an accredited outsourced
laboratory. Constipation symptoms will be assessed using
the validated Patient Assessment of Constipation
Symptoms (PAC-SYM) questionnaire.42 43 This self-
reported questionnaire includes 12 constipation-related
symptoms grouped into three subscales related to
abdominal, stool and rectal symptoms. PAC-SYM is rated
on a ﬁve-point scale, from 0 (no symptom) to 4 (very
severe), aiming to measure the severity of gastrointes-
tinal discomfort over the previous 2 weeks. A reduction
in score (total or subscale) will reﬂect an improvement
in symptoms. Cultural adaptation and linguistic valid-
ation of the PAC-SYM for Portugal was performed by the
Mapi Research Trust (France).44
The change in blood glucose response will be calcu-
lated by computing the difference between the blood
glucose concentration at 30, 60 and 120 min after bread
intake and the baseline (t=0). Capillary ﬁnger-stick
blood samples will be measured using a glucometre
(Glucocard MX, ARKRAY Factory). The total blood
Table 2 Schedule of assessments
Follow-up
Run-in 1st intake Washout 2nd intake
Variables 1 week 2 weeks 4 weeks 6 weeks 9 weeks 11 weeks 13 weeks 15 weeks
Visit x x x x
Blood sample
Total cholesterol xf xf xf xf
Triglycerides xf xf xf xf
HDL cholesterol xf xf xf xf
LDL cholesterol xf xf xf xf
C reactive protein xf xf xf xf
Insulin xf xf xf xf
Glucose xf xf xf xf
Capillary blood glucose xg xg xg xg
Stool sample




xd xd xd xd xd xd xd xd
Stool frequency and consistency xd xd xd xd xd xd xd xd
PAC-SYM x x x x x x x
PAC-QOL x x x x x x x
PSS x x x x
HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAC-QOL, Patient Assessment of Constipation Quality of Life; PAC-SYM, Patient
Assessment of Constipation Symptoms; PSS, Perceived Stress Scale; xd, daily questionnaire; xf, fasting venous blood sample; xg, capillary
blood glucose at 0, 30, 60 and 120 min after wheat bread (supplemented with wheat germ or placebo) intake.
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glucose response will be expressed as the incremental
area under curve (AUC), ignoring the area under the
baseline, and will be calculated geometrically using the
trapezoidal rule.45
Secondary outcomes
The secondary outcomes in this trial will be to demon-
strate the difference (change) between wheat bread sup-
plemented with wheat germ (6 g) and placebo in (1)
self-reported quality of life related to constipation, (2)
stool frequency and consistency, (3) intestinal micro-
biota and (4) insulin resistance.
Participant’s quality of life will be assessed using the
Patient Assessment of Constipation Quality of Life
(PAC-QOL) questionnaire.46 47 The validated PAC-QOL
is composed of 28 items grouped into four subscales
related to physical discomfort, psychosocial discomfort,
worries and concerns, and satisfaction. This self-reported
questionnaire is rated on a ﬁve-point scale, from 0 to 4
(where 0=at no time/not at all, 4=all the time/
extremely), and is used over a 2-week recall period.
Cultural adaptation and linguistic validation of the
PAC-QOL for Portugal was performed by the Mapi
Research Trust (France).44
Secondary outcomes for stool frequency and consist-
ency will be evaluated by means of self-reported ques-
tionnaires, while intestinal microbiota will be analysed by
real-time quantitative PCR based on DNA extracted
from stool samples.
HOMA-IR will be calculated to determine the degree
of insulin resistance. The following formula will be used:
HOMA-IR=(glucose×insulin)/405, where glucose is
fasting glucose (mg/dL) and insulin is fasting insulin
(mU/mL).48
Confounding variables
In addition to the randomisation protocol, the effect of
wheat germ on gastrointestinal discomfort will be con-
trolled for psychological stress, a confounding variable
known to cause gastrointestinal symptoms. A psychomet-
ric assessment will be carried out using the Perceived
Stress Scale (PSS). This 13-item self-reported question-
naire is designed to measure the degree to which situa-
tions in a person’s life are appraised as stressful. Cultural
adaptation and linguistic validation of the PSS for
Portugal was implemented by Pais-Ribeiro and
Marques.49
Sample size estimation
Sample size calculations have taken into account all the
primary outcome variables. The sample size calculations
determined that 40 participants were required to allow
for an 80% power and 95% conﬁdence level. Based on
previous studies, the assumed difference in mean change
from baseline and the respective SD were 5.0 and
11.0 mg/dL for total cholesterol;50 51 2.0 and 4.0 mg/dL
for HDL cholesterol;50 51 5.0 and 11.0 mg/dL for
LDL cholesterol;50 51 9.0 and 20.0 mg/dL for TG;50 51
0.035 and 0.080 mg/dL for CRP;52 35.0 and 80.0 mmol
min/L for the incremental AUC of postprandial blood
glucose;53 54 and 0.35 and 0.75 for the PAC-SYM score.55
Our aim was to enrol at least 50 participants to allow for
dropouts.
Statistical analysis
Statistical analysis will be performed using SPSS V.23
software (SPSS, Chicago, Illinois, USA). Non-parametric
tests will be used to analyse changes in PAC-SYM and
PAC-QOL scores, since these data are not normally dis-
tributed. All other outcome parameters will be analysed
using parametric approaches. Student’s two-tailed
unpaired t-tests will be used to compare baseline
characteristics between participants. A Student’s
two-tailed paired t-test or repeated measures analysis of
variance (ANOVA) will be used to analyse wheat germ
supplementation effects within groups. The difference
in the mean values of outcome variables between groups
(intervention and control) will be measured using a
Student’s two-tailed unpaired t-test. All reported p values
will be two-sided and tests will be performed with a 5%
level of signiﬁcance. Results will be summarised as
descriptive statistics for baseline, and after 2-week and
4-week intake periods. Changes from baseline will be
also evaluated for weeks 2 and 4.
The crossover design is only feasible in a setting where
the conditions of interest remain stable during the study.
If the conditions change during the study, they will
affect the results, so it is very important to test for
period effect.56 Moreover, the study design includes a
washout period between the two treatment periods. This
washout period aims to minimise the risk of a carry-over
effect from the intervention in period 1 into period 2.
Therefore, to check for any residual carry-over effect, a
test of interaction between treatment and period is also
recommended.56
The statistical analysis will be performed applying an
intention-to-treat (ITT) approach, Chichester, UK: John
Wiley & Sons, with all randomised participants included
in the analysis. It will make two main assumptions (in
addition to the normality assumption for Student’s
paired and unpaired t-tests): no period effect and no
carry-over effect (assessed by the treatment–period inter-
action). These two assumptions will be tested using the
methods recommended by Pocock.56 If the period effect
is signiﬁcant, the analysis will be adjusted in order to
take the period effect into consideration.56 Moreover, if
the carry-over effect (interaction between treatment and
period) is signiﬁcant, only the ﬁrst period will be used in
the analysis, also following Pocock’s recommendations.56
The PAC-SYM and PAC-QOL total score and subscale
scores will be computed based on non-missing item
responses. If more than 50% of items in the total scale/
subscale are missing, the total scale/subscale score is not
calculated and will be designated as ‘missing’. For these
previously described parameters, non-parametric tests
will be used, as these data are not normally distributed.
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Changes within and between groups will be checked
with the Wilcoxon matched-pairs signed-rank test or the
Mann-Whitney test, as appropriate.
ETHICS AND DISSEMINATION
All participants provided written informed consent. Any
major amendments to the approved protocol will be
resubmitted to the Ethics Committees. The trial has
been conducted in accordance with the ethical princi-
ples of the Declaration of Helsinki, international law
and Good Clinical Practice guidelines. Data monitoring
has been performed by research coordinators along the
study recruitment and follow-up an independent data
monitoring committee has not been established for this
study due to its minimal risk for human health. This
trial was registered in ClinicalTrials.gov Database, refer-
ence NCT02405507, on 11 March 2015. The results
from this study will be disseminated through peer-
reviewed publications and presentations at international
scientiﬁc meetings.
DISCUSSION
There is some evidence to suggest that wheat germ has a
beneﬁcial physiological effect in maintaining normal
cholesterol levels19 20 and in decreasing potentially
pathogenic gastrointestinal microorganisms.21 However,
existing studies are scarce and have relevant design lim-
itations, namely small sample size and insufﬁcient infor-
mation on study design (eg, sample size calculation,
allocation concealment and blinding/masking). Thus,
they are still inconclusive regarding the potential causal
relationship between wheat germ intake and its alleged
health beneﬁts. Moreover, all these studies have used
wheat germ as a supplement. Given that bread is one of
the most widely consumed food products57 and that the
majority of consumers prefer whiter and softer bread
formulations,23 58 the aim was to create a wheat
germ-enriched bread that preserved the taste and
texture of reﬁned white bread. Consequently, we expect
that even a small health beneﬁt effect, if observed, could
lead to a major impact on public health.
To the best of our knowledge, this is the ﬁrst clinical
trial to assess the impact of wheat germ-enriched bread
intake in healthy individuals. Furthermore, this study
has used outcomes which are considered to be beneﬁ-
cial physiological effects, according to the EFSA. Hence,
this randomised crossover controlled trial could have an
important contribution to make for the research com-
munity, mainly for those who are facing challenges in
providing scientiﬁc evidence for the physiological bene-
ﬁts of food derivatives for human health.
Author affiliations
1Centre for Health Technology and Services Research (CINTESIS), Faculty of
Medicine, University of Porto, Porto, Portugal
2Department of Biochemistry, Faculty of Medicine, University of Porto, Porto,
Portugal
3Department of Health Information and Decision Sciences (CIDES), Faculty of
Medicine, University of Porto, Porto, Portugal
4Serviço de Doenças Infecciosas, Centro Hospitalar de Lisboa Central,
Hospital de Curry Cabral, Lisbon, Portugal
5Department of Nutrition and Metabolism, NOVA Medical School, NOVA
University of Lisbon, Lisbon, Portugal
Acknowledgements The authors are grateful to all participants for their
participation in this study. They thank Padaria Ribeiro for the production of
bread used in the trial. They thank R Shackleford for proofreading this
protocol manuscript.
Contributors AMR was partially responsible for study design, statistical
analysis plan, carrying out the trial, protocol manuscript writing and final
revision. HP was partially responsible for study design, carrying out the trial,
manuscript writing and final revision. CC was responsible for the general
coordination of the project, study design, protocol manuscript writing and
final revision. LFA was responsible for the general coordination of the project,
study design, statistical analysis plan, protocol manuscript writing and final
revision.
Funding This work was supported by FEDER through the operations FCOMP-
01-0202-FEDER-038861 and POCI-01-0145-FEDER-007746 funded by the
Programa Operacional Competitividade e Internacionalização – COMPETE2020
and by National Funds through FCT - Fundação para a Ciência e a Tecnologia
within CINTESIS, R&D Unit (reference UID/IC/4255/2013).
Disclaimer The funder had no role in study design and will not have any role
during its execution, analyses, interpretation of the data, or decision to submit
results.
Competing interests None declared.
Ethics approval Health Ethics Committee of São João Hospital Centre
(reference 156-15) and the Ethics Committee of the Faculty of Medicine of the
University of Porto (reference PCEDCSS-FMUP 07/2015).
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. McGee DL, Reed DM, Yano K, et al. Ten-year incidence of coronary
heart disease in the Honolulu Heart Program. Relationship to
nutrient intake. Am J Epidemiol 1984;119:667–76.
2. Michas G, Micha R, Zampelas A. Dietary fats and cardiovascular
disease: putting together the pieces of a complicated puzzle.
Atherosclerosis 2014;234:320–8.
3. Schwingshackl L, Hoffmann G. Dietary fatty acids in the
secondary prevention of coronary heart disease: a systematic
review, meta-analysis and meta-regression. BMJ Open 2014;4:
e004487.
4. Willett W, Manson J, Liu S. Glycemic index, glycemic load, and risk
of type 2 diabetes. Am J Clin Nutr 2002;76:274S–80S.
5. Hauner H, Bechthold A, Boeing H, et al. Evidence-based guideline
of the German Nutrition Society: carbohydrate intake and prevention
of nutrition-related diseases. Ann Nutr Metab 2012;60(Suppl
1):1–58.
6. Esposito K, Maiorino MI, Bellastella G, et al. A journey into a
Mediterranean diet and type 2 diabetes: a systematic review with
meta-analyses. BMJ Open 2015;5:e008222.
7. de Jong N, Hoendervangers CT, Bleeker JK, et al. The opinion of
Dutch dietitians about functional foods. J Hum Nutr Diet
2004;17:55–62.
8. Vella MN, Stratton LM, Sheeshka J, et al. Functional food
awareness and perceptions in relation to information sources in older
adults. Nutr J 2014;13:44.
9. Zong G, Gao A, Hu FB, et al. Whole grain intake and mortality from
all causes, cardiovascular disease, and cancer: a meta-analysis of
prospective cohort studies. Circulation 2016;133:2370–80.
Moreira-Rosário A, et al. BMJ Open 2016;6:e013098. doi:10.1136/bmjopen-2016-013098 7
Open Access
10. Aune D, Keum N, Giovannucci E, et al. Whole grain consumption
and risk of cardiovascular disease, cancer, and all cause and cause
specific mortality: systematic review and dose-response
meta-analysis of prospective studies. BMJ 2016;353:i2716.
11. Whitehead A, Beck EJ, Tosh S, et al. Cholesterol-lowering effects of
oat β-glucan: a meta-analysis of randomized controlled trials. Am
J Clin Nutr 2014;100:1413–21.
12. European Food Safety Authority. Scientific Opinion on the
substantiation of health claims related to beta glucans and
maintenance of normal blood cholesterol concentrations (ID 754, 755,
757, 801, 1465, 2934) and maintenance or achievement of a normal
body weight (ID 820, 823) pursuant to Article 13(1) of Regulation
(EC) No 1924/2006. EFSA Journal 2009; 7(9):1254. http://www.efsa.
europa.eu/en/efsajournal/pub/1254 (accessed 13 Jan 2016).
13. European Food Safety Authority. Scientific Opinion on the
substantiation of health claims related to walnuts and maintenance
of normal blood LDL-cholesterol concentrations (ID 1156, 1158) and
improvement of endothelium-dependent vasodilation (ID 1155, 1157)
pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA
Journal 2011;9(4):2074. http://www.efsa.europa.eu/en/efsajournal/
pub/2074 (accessed 13 Jan 2016).
14. Brandolini A, Hidalgo A. Wheat germ: not only a by-product. Int
J Food Sci Nutr 2012;63(Suppl 1):71–4.
15. Ge Y, Sun A, Ni Y, et al. Some nutritional and functional properties
of defatted wheat germ protein. J Agric Food Chem
2000;48:6215–18.
16. Zhou C, Ma H, Yu X, et al. Pretreatment of defatted wheat germ
proteins (by-products of flour mill industry) using ultrasonic horn and
bath reactors: effect on structure and preparation of ACE-inhibitory
peptides. Ultrason Sonochem 2013;20:1390–400.
17. Lairon D, Lacombe C, Borel P, et al. Beneficial effect of wheat germ
on circulating lipoproteins and tissue lipids in rats fed a high fat,
cholesterol-containing diet. J Nutr 1987;117:838–45.
18. Cara L, Borel P, Armand M, et al. Effects of increasing levels of raw
or defatted wheat germ on liver, feces and plasma lipids and
lipoproteins in the rat. Nutrition Res 1991;11:907–16.
19. Cara L, Borel P, Armand M, et al. Plasma lipid lowering effects of
wheat germ in hypercholesterolemic subjects. Plant Foods Hum Nutr
1991;41:135–50.
20. Cara L, Armand M, Borel P, et al. Long-term wheat germ intake
beneficially affects plasma lipids and lipoproteins in
hypercholesterolemic human subjects. J Nutr 1992;122:317–26.
21. Matteuzzi D, Swennen E, Rossi M, et al. Prebiotic effects of a wheat
germ preparation in human healthy subjects. Food Microbiology
2004;21:119–24.
22. van Bakel MM, Kaaks R, Feskens EJ, et al. Dietary glycaemic index
and glycaemic load in the European prospective investigation into
cancer and nutrition. Eur J Clin Nutr 2009;63(Suppl 4):S188–205.
23. Burton PM, Monro JA, Alvarez L, et al. Glycemic impact and health:
new horizons in white bread formulations. Crit Rev Food Sci Nutr
2011;51:965–82.
24. Brand-Miller J, Hayne S, Petocz P, et al. Low-glycemic index diets in
the management of diabetes: a meta-analysis of randomized
controlled trials. Diabetes Care 2003;26:2261–7.
25. Stein EA, Raal FJ. Targeting LDL: is lower better and is it safe? Best
Pract Res Clin Endocrinol Metab 2014;28:309–24.
26. European Food Safety Authority. Guidance on the scientific
requirements for health claims related to antioxidants, oxidative
damage and cardiovascular health. EFSA Journal 2011;9(12):2474.
http://www.efsa.europa.eu/en/efsajournal/pub/2474 (accessed 13
Jan 2016).
27. Ahmadi-Abhari S, Luben RN, Wareham NJ, et al. Seventeen year
risk of all-cause and cause-specific mortality associated with
C-reactive protein, fibrinogen and leukocyte count in men and
women: the EPIC-Norfolk study. Eur J Epidemiol
2013;28:541–50.
28. European Food Safety Authority. Scientific Opinion on the
substantiation of health claims related to astaxanthin and
maintenance of joints, tendons, and connective tissue (ID 1918,
1978, 3142), protection of DNA, proteins and lipids from oxidative
damage (ID 1449, 3141), maintenance of visual acuity (ID 1448),
maintenance of blood cholesterol concentrations and maintenance
of low plasma concentrations of C-reactive protein (ID 1450)
pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA
Journal 2009; 7(9):1253. http://www.efsa.europa.eu/en/efsajournal/
pub/1253 (accessed 13 Jan 2016).
29. Fardet A. New hypotheses for the health-protective mechanisms of
whole-grain cereals: what is beyond fibre? Nutr Res Rev
2010;23:65–134.
30. Scazzina F, Siebenhandl-Ehn S, Pellegrini N. The effect of dietary fibre
on reducing the glycaemic index of bread. Br J Nutr 2013;109:1163–74.
31. Anand SS, Hawkes C, de Souza RJ, et al. Food consumption and
its impact on cardiovascular disease: importance of solutions
focused on the globalized food system: a report from the workshop
convened by the World Heart Federation. J Am Coll Cardiol
2015;66:1590–614.
32. Reaven G. Insulin resistance and coronary heart disease in
nondiabetic individuals. Arterioscler Thromb Vasc Biol
2012;32:1754–9.
33. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in
cardiovascular disease development. Nat Rev Endocrinol
2014;10:293–302.
34. Fedor D, Kelley DS. Prevention of insulin resistance by n-3
polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care
2009;12:138–46.
35. Meyer D, Stasse-Wolthuis M. The bifidogenic effect of inulin and
oligofructose and its consequences for gut health. Eur J Clin Nutr
2009;63:1277–89.
36. Shen W, Gaskins HR, McIntosh MK. Influence of dietary fat on
intestinal microbes, inflammation, barrier function and metabolic
outcomes. J Nutr Biochem 2014;25:270–80.
37. European Food Safety Authority. Scientific Opinion on the
substantiation of health claims related to decreasing potentially
pathogenic gastro-intestinal microorganisms (ID 785) pursuant to
Article 13(1) of Regulation (EC) No 1924/20061. EFSA Journal
2011;9(6):2256. http://www.efsa.europa.eu/sites/default/files/
scientific_output/files/main_documents/2256.pdf (accessed 15 Sep
2015).
38. Mugie SM, Benninga MA, Di Lorenzo C. Epidemiology of
constipation in children and adults: a systematic review. Best Pract
Res Clin Gastroenterol 2011;25:3–18.
39. European Food Safety Authority. General scientific guidance for
stakeholders on health claim applications. EFSA Journal 2016;14
(1):4367. http://www.efsa.europa.eu/en/efsajournal/pub/4367
(accessed 13 Jan 2016).
40. European Food Safety Authority. Scientific opinion on the
substantiation of health claims related to various food(s)/food
constituents(s) and increasing numbers of gastro-intestinal
microorganisms (ID 760, 761, 779, 780, 779, 1905), and
decreasing potentially pathogenic gastro-intestinal microorganisms
(ID 760, 761, 779, 780, 779, 1905) pursuant to Article 13(1) of
Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1809.
http://www.efsa.europa.eu/en/efsajournal/pub/1809 (accessed 13
Jan 2016).
41. European Food Safety Authority. Scientific opinion on the
substantiation of health claims related to fructo-oligosaccharides
(FOS) and decreasing potentially pathogenic gastro-intestinal
microorganisms (ID 781) pursuant to Article 13(1) of Regulation
(EC) No 1924/2006. EFSA Journal 2011;9(6):2222. http://www.
efsa.europa.eu/en/efsajournal/pub/2222. (accessed 13 Jan
2016).
42. Frank L, Kleinman L, Farup C, et al. Psychometric validation of a
constipation symptom assessment questionnaire. Scand
J Gastroenterol 1999;34:870–7.
43. Slappendel R, Simpson K, Dubois D, et al. Validation of the
PAC-SYM questionnaire for opioid-induced constipation in
patients with chronic low back pain. Eur J Pain
2006;10:209–17.
44. Mapi Research Trust. http://www.mapi-trust.org. (accessed 25 Feb
2015).
45. Wolever TMS. The glycaemic index: a physiological classification of
dietary carbohydrate. Oxfordshire: CABI, 2006.
46. Marquis P, De La Loge C, Dubois D, et al. Development and
validation of the Patient Assessment of Constipation Quality of Life
questionnaire. Scand J Gastroenterol 2005;40:540–51.
47. Dubois D, Gilet H, Viala-Danten M, et al. Psychometric performance
and clinical meaningfulness of the Patient Assessment of
Constipation-Quality of Life questionnaire in prucalopride
(RESOLOR) trials for chronic constipation. Neurogastroenterol Motil
2010;22:e54–63.
48. Ostrowska L, Witczak K, Adamska E. Effect of nutrition and
atherogenic index on the occurrence and intensity of insulin
resistance. Pol Arch Med Wewn 2013;123:289–96.
49. Pais-Ribeiro J, Marques T. A avaliação do stresse: a propósito de
um estudo de adaptação da escala de percepção de stresse. Psicol
Saúde Doenças 2009;10:237–48.
50. Kuriyan R, Kumar DR, R R, et al. An evaluation of the hypolipidemic
effect of an extract of Hibiscus Sabdariffa leaves in hyperlipidemic
Indians: a double blind, placebo controlled trial. BMC Complement
Altern Med 2010;10:27.
51. Lee SH, Park S, Kang SM, et al. Effect of atorvastatin monotherapy
and low-dose atorvastatin/ezetimibe combination on fasting and
8 Moreira-Rosário A, et al. BMJ Open 2016;6:e013098. doi:10.1136/bmjopen-2016-013098
Open Access
postprandial triglycerides in combined hyperlipidemia. J Cardiovasc
Pharmacol Ther 2012;17:65–71.
52. Skulas-Ray AC, Flock MR, Richter CK, et al. Red blood cell
docosapentaenoic acid (DPA n-3) is inversely associated with
triglycerides and C-reactive protein (CRP) in healthy adults and
dose-dependently increases following n-3 fatty acid
supplementation. Nutrients 2015;7:6390–404.
53. Tapola N, Karvonen H, Niskanen L, et al. Glycemic responses of oat
bran products in type 2 diabetic patients. Nutr Metab Cardiovasc Dis
2005;15:255–61.
54. Sonia S, Witjaksono F, Ridwan R. Effect of cooling of cooked white
rice on resistant starch content and glycemic response. Asia Pac
J Clin Nutr 2015;24:620–5.
55. Tack J, Stanghellini V, Dubois D, et al. Effect of prucalopride on
symptoms of chronic constipation. Neurogastroenterol Motil
2014;26:21–7.
56. Pocock SJ. Clinical trials: a practical approach. Chichester, UK:
John Wiley & Sons Ltd, 1983.
57. Cust AE, Skilton MR, van Bakel MM, et al. Total dietary
carbohydrate, sugar, starch and fibre intakes in the European
Prospective Investigation into Cancer and Nutrition. Eur J Clin Nutr
2009;63(Suppl 4):S37–60.
58. Whitton C, Nicholson SK, Roberts C, et al. National Diet and
Nutrition Survey: UK food consumption and nutrient intakes from the
first year of the rolling programme and comparisons with previous
surveys. Br J Nutr 2011;106:1899–914.
Moreira-Rosário A, et al. BMJ Open 2016;6:e013098. doi:10.1136/bmjopen-2016-013098 9
Open Access
